シンバイオ製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2021/11/15 | 1,347 | 1,347 | 1,347 | 1,347 | +300 | +28.7% | 317,600 |
2021/11/12 | 1,047 | 1,047 | 1,047 | 1,047 | +150 | +16.7% | 163,700 |
2021/11/11 | 931 | 934 | 890 | 897 | -25 | -2.7% | 1,782,200 |
2021/11/10 | 930 | 952 | 913 | 922 | -8 | -0.9% | 1,015,400 |
2021/11/09 | 943 | 963 | 925 | 930 | -15 | -1.6% | 1,320,200 |
2021/11/08 | 992 | 1,002 | 934 | 945 | -54 | -5.4% | 2,122,400 |
2021/11/05 | 1,039 | 1,039 | 990 | 999 | -40 | -3.8% | 1,545,200 |
2021/11/04 | 1,039 | 1,065 | 1,025 | 1,039 | +14 | +1.4% | 807,500 |
2021/11/02 | 1,038 | 1,051 | 1,020 | 1,025 | ±0 | ±0% | 731,700 |
2021/11/01 | 1,070 | 1,080 | 1,018 | 1,025 | -43 | -4% | 1,197,800 |
2021/10/29 | 1,099 | 1,109 | 1,064 | 1,068 | -22 | -2% | 1,346,600 |
2021/10/28 | 1,081 | 1,107 | 1,072 | 1,090 | -1 | -0.1% | 1,219,600 |
2021/10/27 | 1,065 | 1,114 | 1,047 | 1,091 | +22 | +2.1% | 2,332,000 |
2021/10/26 | 1,002 | 1,085 | 999 | 1,069 | +67 | +6.7% | 2,767,900 |
2021/10/25 | 1,015 | 1,032 | 976 | 1,002 | +26 | +2.7% | 1,978,500 |
2021/10/22 | 965 | 994 | 958 | 976 | +12 | +1.2% | 1,059,600 |
2021/10/21 | 1,013 | 1,032 | 961 | 964 | -56 | -5.5% | 2,177,700 |
2021/10/20 | 1,030 | 1,033 | 1,008 | 1,020 | -7 | -0.7% | 703,000 |
2021/10/19 | 1,009 | 1,034 | 1,003 | 1,027 | +14 | +1.4% | 751,200 |
2021/10/18 | 1,039 | 1,060 | 1,006 | 1,013 | -26 | -2.5% | 1,279,600 |
2021/10/15 | 993 | 1,047 | 993 | 1,039 | +45 | +4.5% | 2,035,700 |
2021/10/14 | 1,005 | 1,013 | 983 | 994 | -15 | -1.5% | 1,058,500 |
2021/10/13 | 1,002 | 1,028 | 995 | 1,009 | +1 | +0.1% | 703,300 |
2021/10/12 | 1,047 | 1,072 | 1,001 | 1,008 | -14 | -1.4% | 1,639,600 |
2021/10/11 | 1,001 | 1,024 | 996 | 1,022 | +21 | +2.1% | 796,100 |
2021/10/08 | 992 | 1,009 | 982 | 1,001 | +24 | +2.5% | 992,700 |
2021/10/07 | 973 | 1,011 | 967 | 977 | +4 | +0.4% | 1,586,500 |
2021/10/06 | 1,003 | 1,011 | 960 | 973 | -11 | -1.1% | 1,053,500 |
2021/10/05 | 989 | 998 | 951 | 984 | -25 | -2.5% | 1,341,000 |
2021/10/04 | 1,043 | 1,044 | 991 | 1,009 | -20 | -1.9% | 1,153,900 |
2021/10/01 | 1,025 | 1,050 | 1,015 | 1,029 | +2 | +0.2% | 957,200 |
2021/09/30 | 1,066 | 1,078 | 1,025 | 1,027 | -38 | -3.6% | 1,203,000 |
2021/09/29 | 1,030 | 1,089 | 1,015 | 1,065 | +22 | +2.1% | 1,744,200 |
2021/09/28 | 1,059 | 1,073 | 1,037 | 1,043 | -16 | -1.5% | 889,500 |
2021/09/27 | 1,058 | 1,078 | 1,029 | 1,059 | -10 | -0.9% | 1,587,300 |
2021/09/24 | 994 | 1,082 | 994 | 1,069 | +102 | +10.5% | 3,255,300 |
2021/09/22 | 1,049 | 1,054 | 940 | 967 | -79 | -7.6% | 4,396,500 |
2021/09/21 | 1,016 | 1,063 | 1,016 | 1,046 | -24 | -2.2% | 1,053,600 |
2021/09/17 | 1,042 | 1,071 | 1,032 | 1,070 | +12 | +1.1% | 1,328,200 |
2021/09/16 | 1,081 | 1,087 | 1,032 | 1,058 | -19 | -1.8% | 2,016,200 |
2021/09/15 | 1,076 | 1,094 | 1,068 | 1,077 | -10 | -0.9% | 997,400 |
2021/09/14 | 1,106 | 1,111 | 1,068 | 1,087 | -26 | -2.3% | 2,115,500 |
2021/09/13 | 1,126 | 1,138 | 1,105 | 1,113 | -16 | -1.4% | 1,259,000 |
2021/09/10 | 1,133 | 1,150 | 1,122 | 1,129 | +3 | +0.3% | 1,430,900 |
2021/09/09 | 1,131 | 1,165 | 1,117 | 1,126 | -14 | -1.2% | 1,563,400 |
2021/09/08 | 1,168 | 1,183 | 1,125 | 1,140 | -39 | -3.3% | 3,033,300 |
2021/09/07 | 1,119 | 1,214 | 1,100 | 1,179 | +65 | +5.8% | 4,884,000 |
2021/09/06 | 1,122 | 1,143 | 1,104 | 1,114 | +1 | +0.1% | 1,551,900 |
2021/09/03 | 1,089 | 1,116 | 1,071 | 1,113 | +32 | +3% | 1,588,300 |
2021/09/02 | 1,123 | 1,123 | 1,075 | 1,081 | -42 | -3.7% | 1,719,900 |
851~
900
件表示中 / 3314件
類似銘柄と比較する
現在ご覧いただいている「シンバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
シンバイオ | 15,500円 | -24.2% | - | 0.00% | - | 1.95倍 |
|
導入で新薬開発・製品化。抗がん剤「トレアキシン」国内販売。抗ウイルス薬BCVの開発に注力 |
ケイファーマ | 74,300円 | - | - | 0.00% | - | 3.82倍 |
|
慶応大学発ベンチャー。iPS細胞による再生医療と創薬の2本柱。中枢神経系が得意領域 |
サイフューズ | 97,200円 | +459.3% | - | 0.00% | - | 3.24倍 |
|
バイオ3Dプリンタを開発、自家細胞製品の製造受託も。臓器など再生医療等製品を臨床開発中 |
ソレイジア | 3,300円 | +311.4% | - | 0.00% | - | 6.23倍 |
|
がん柱の創薬ベンチャー。候補品導入後に開発進め権利再導出、製品販売を行うビジネスモデル |
日ケミファ | 153,000円 | +2.5% | - | 3.27% | 92.00倍 | 0.30倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
市場注目の銘柄
チャート関連のコラム